Trial Condition(s):

Colorectal Neoplasm

Investigating the use of regorafenib (Stivarga®) in patients with metastatic colorectal cancer (mCRC) after failure of standard therapy (RECORA)

Bayer Identifier:

16665

ClinicalTrials.gov Identifier:

NCT01959269

EudraCT Number:

Not Available

Study Completed

Trial Purpose

The purpose of the study is to investigate the safety and effectiveness of Stivarga in patients with metastatic colorectal carcinoma in routine use in Germany. The study is purely observational, only data from routine treatment are to be collected. The treatment and treatment conditions are solely at discretion of the treating physician.

Inclusion Criteria
No Inclusion Criteria Available
Exclusion Criteria
Inclusion Criteria:´
  - Male or female patients ≥ 18 years of age with metastatic CRC for whom the decision has been taken by the investigator to treat with Stivarga. 
  - Patients must have signed an informed consent form

Trial Summary

Enrollment Goal
483
Trial Dates
black-arrow
Phase
N/A
Could I receive a placebo?
No
Products
Stivarga (Regorafenib, BAY73-4506)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Investigative Site

Many Locations, Germany

Status
Completed
 

Trial Design